During the Osteoporotic Fractures in Men Study (MrOS) baseline examination from 2000 to 2002, 5,994 community-dwelling men 65 years or older were enrolled at 6 clinical centers in the United States: Birmingham, Alabama; Minneapolis, Minnesota; Palo Alto, California; the Monongahela Valley near Pittsburgh, Pennsylvania; Portland, Oregon; and San Diego, California.33 (link),34 (link) In order to participate, men needed to be able to walk without assistance and must not have had a bilateral hip replacement.
The MrOS Sleep Study, an ancillary study of the parent MrOS cohort, was conducted between December 2003 and March 2005 and recruited 3,135 of these participants (exceeding the goal of 3,000 participants) for a comprehensive sleep assessment. Men were screened for nightly use of mechanical devices during sleep including pressure mask for sleep apnea [CPAP or bilevel positive airway pressure (BiPAP)], mouthpiece for snoring or sleep apnea, or oxygen therapy and were generally excluded. Of the 2,859 men who did not participant in this ancillary study, 344 died before the sleep visit, 36 had already terminated the study, 332 were not asked because recruitment goals had already been met, 150 were not eligible, and 1,997 refused. Cognitive function data was available for 3,132 men. Of these, 2,909 had in-home overnight polysomnography (PSG) recordings and comprise our analytic cohort. All men with PSG data had information on SDB and nocturnal hypoxemia. Of the 2,909 PSG recordings, 39 had no data available on sleep architecture.
All men provided written informed consent, and the study was approved by the Institutional Review Board at each site.
The MrOS Sleep Study, an ancillary study of the parent MrOS cohort, was conducted between December 2003 and March 2005 and recruited 3,135 of these participants (exceeding the goal of 3,000 participants) for a comprehensive sleep assessment. Men were screened for nightly use of mechanical devices during sleep including pressure mask for sleep apnea [CPAP or bilevel positive airway pressure (BiPAP)], mouthpiece for snoring or sleep apnea, or oxygen therapy and were generally excluded. Of the 2,859 men who did not participant in this ancillary study, 344 died before the sleep visit, 36 had already terminated the study, 332 were not asked because recruitment goals had already been met, 150 were not eligible, and 1,997 refused. Cognitive function data was available for 3,132 men. Of these, 2,909 had in-home overnight polysomnography (PSG) recordings and comprise our analytic cohort. All men with PSG data had information on SDB and nocturnal hypoxemia. Of the 2,909 PSG recordings, 39 had no data available on sleep architecture.
All men provided written informed consent, and the study was approved by the Institutional Review Board at each site.
